Description

3-Hydroxy-α-Methyl-o-(1-Pivaloylethyl)-L-Tyrosine Hydrogen [R-(R*,R*)]-Tartrate is a high-purity, stereochemically defined synthetic intermediate of significant importance in advanced pharmaceutical research and development. This compound is valued for its role as a key chiral building block in the synthesis of complex, biologically active molecules, particularly those targeting neurological and cardiovascular pathways. It is primarily utilized by pharmaceutical R&D laboratories and fine chemical manufacturers engaged in the production of novel active pharmaceutical ingredients (APIs).

Application

• Pharmaceutical Intermediate: A critical chiral precursor in the multi-step synthesis of complex drug candidates, particularly for central nervous system (CNS) and cardiovascular therapeutics.
• Peptidomimetic Research: Serves as a modified tyrosine analog for constructing peptide-like molecules with enhanced metabolic stability and receptor selectivity.
• Asymmetric Synthesis: Used as a starting material or intermediate in stereoselective chemical reactions to introduce specific chiral centers into target molecules.
• Medicinal Chemistry: Employed in structure-activity relationship (SAR) studies to explore new chemical entities and optimize pharmacological profiles.
• Reference Standard: Can be supplied as a high-purity analytical standard for method development and quality control in API manufacturing.
• Process Chemistry Development: Used for scaling up and optimizing synthetic routes from laboratory to pilot plant scale.

Basic Information

Product Name	3-Hydroxy-α-Methyl-o-(1-Pivaloylethyl)-L-Tyrosine Hydrogen [R-(R*,R*)]-Tartrate
CAS No.	81972-28-3
Molecular Formula	C₂₁H₃₁NO₉
Molecular Weight	441.47 g/mol
Synonyms	L-Tyrosine, 3-hydroxy-α-methyl-O-[1-(2,2-dimethyl-1-oxopropoxy)ethyl]-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1); (2S)-2-Amino-3-[4-hydroxy-3-([(2R)-1-[(2,2-dimethylpropanoyl)oxy]propan-2-yl]oxy)phenyl]-2-methylpropanoic acid compound with (2R,3R)-2,3-dihydroxybutanedioic acid; AT1 Antagonist Intermediate; Valsartan Synthetic Intermediate; SC-52458 Intermediate; (S)-3-(4-Hydroxy-3-{[(1R)-1-((2,2-dimethylpropanoyl)oxy)ethyl]oxy}phenyl)-2-methylalanine (2R,3R)-Tartrate Salt
EINECS	Contact for details

Quality Control

Our 3-Hydroxy-α-Methyl-o-(1-Pivaloylethyl)-L-Tyrosine Hydrogen [R-(R*,R*)]-Tartrate is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing, including HPLC for purity and chiral assay, NMR for structural confirmation, and residual solvent analysis to ensure it meets the stringent requirements for pharmaceutical R&D. A detailed Certificate of Analysis (COA) documenting identity, purity, and specific impurities is provided with every shipment.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). The compound is light-sensitive (store away from light). For long-term storage, consider storage under inert atmosphere to ensure stability.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time corresponds to reference standard
Assay (HPLC)	≥ 98.0%
Chiral Purity (HPLC)	≥ 99.0% ee
Loss on Drying	≤ 0.5%
Residual Solvents (GC)	Meets ICH Q3C guidelines
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.